Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T84631
|
||||
Former ID |
TTDS00203
|
||||
Target Name |
Coagulation factor Xa
|
||||
Gene Name |
F10
|
||||
Synonyms |
Activated coagulation factor X; Factor Xa; Fxa; F10
|
||||
Target Type |
Successful
|
||||
Disease | Attention deficit hyperactivity disorder [ICD9: 314; ICD10: F90] | ||||
Atrial fibrillation [ICD9: 272, 427.31; ICD10: E78, I48] | |||||
Acute coronary syndrome [ICD9: 444; ICD10: I74] | |||||
Angina pectoris [ICD9: 413; ICD10: I20] | |||||
Bleeding [ICD9: 444, 453; ICD10: I74, I80-I82] | |||||
Blood coagulation disorders [ICD10: D65-D68] | |||||
Coagulation [ICD10: I80-I82] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Deep vein thrombosis [ICD9: 437.6, 453, 453.40, 671.5, 671.9; ICD10: I80-I82, I80.2] | |||||
Deep venous clots [ICD9: 453.4; ICD10: I80.2] | |||||
Hematology [ICD10: D50-D77] | |||||
Hemophilia [ICD9: 286; ICD10: D66-D68] | |||||
Haemophilia B; Christmas disease [ICD9:286.1; ICD10: D67] | |||||
Prophylaxis of deep vein thrombosis [ICD9: 437.6, 453, 453.40, 671.5, 671.9; ICD10: I80-I82, I80.2] | |||||
Renal cancer [ICD9: 140-229, 189; ICD10: C64] | |||||
Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82] | |||||
Thromboembolism [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82] | |||||
Thromboembolic disorders [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82] | |||||
Venous thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82] | |||||
Venous thromboembolism [ICD9: 453; ICD10: I80-I82] | |||||
Unspecified [ICD code not available] | |||||
Function |
Factor Xa is avitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
|
||||
BioChemical Class |
Peptidase
|
||||
Target Validation |
T84631
|
||||
UniProt ID | |||||
EC Number |
EC 3.4.21.6
|
||||
Sequence |
MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE VITSSPLK |
||||
Structure |
1C5M; 1EZQ; 1F0R; 1F0S; 1FAX; 1FJS; 1FXY; 1G2L; 1G2M; 1HCG; 1IOE; 1IQE; 1IQF; 1IQG; 1IQH; 1IQI; 1IQJ; 1IQK; 1IQL; 1IQM; 1IQN; 1KSN; 1LPG; 1LPK; 1LPZ; 1LQD; 1MQ5; 1MQ6; 1MSX; 1NFU; 1NFW; 1NFX; 1NFY; 1NL8; 1P0S; 1V3X; 1WU1; 1XKA; 1XKB; 1Z6E; 2BMG; 2BOH; 2BOK; 2BQ6; 2BQ7; 2BQW; 2CJI; 2D1J; 2EI6; 2EI7; 2EI8; 2FZZ; 2G00; 2GD4; 2H9E; 2J2U; 2J34; 2J38; 2J4I; 2J94; 2J95; 2JKH; 2P16; 2P3F; 2P3T; 2P3U; 2P93; 2P94; 2P95; 2PHB; 2PR3; 2Q1J; 2RA0;2UWL; 2UWO; 2UWP; 2VH0; 2VH6; 2VVC; 2VVU; 2VVV; 2VWL; 2VWM; 2VWN; 2VWO; 2W26; 2W3I; 2W3K; 2WYG; 2WYJ; 2XBV; 2XBW; 2XBX; 2XBY; 2XC0; 2XC4; 2XC5; 2Y5F; 2Y5G; 2Y5H; 2Y7X; 2Y7Z; 2Y80; 2Y81; 2Y82; 3CEN; 3CS7; 3ENS; 3FFG; 3HPT; 3IIT; 3K9X; 3KL6; 3KQB; 3KQC; 3KQD; 3KQE; 3LIW; 3M36; 3M37; 3Q3K; 3SW2; 3TK5; 3TK6; 4A7I; 4BTI; 4BTT; 4BTU; 1C5M; 1EZQ; 1F0R; 1F0S; 1FAX; 1FJS; 1FXY; 1G2L; 1G2M; 1HCG; 1IOE; 1IQE; 1IQF; 1IQG; 1IQH; 1IQI; 1IQJ; 1IQK; 1IQL; 1IQM; 1IQN; 1KSN; 1LPG; 1LPK; 1LPZ; 1LQD; 1MQ5; 1MQ6; 1MSX; 1NFU; 1NFW; 1NFX; 1NFY; 1NL8; 1P0S; 1V3X; 1WU1; 1XKA; 1XKB; 1Z6E; 2BMG; 2BOH; 2BOK; 2BQ6; 2BQ7; 2BQW; 2CJI; 2D1J; 2EI6; 2EI7; 2EI8; 2FZZ; 2G00; 2GD4; 2H9E; 2J2U; 2J34; 2J38; 2J4I; 2J94; 2J95; 2JKH; 2P16; 2P3F; 2P3T; 2P3U; 2P93; 2P94; 2P95; 2PHB; 2PR3; 2Q1J; 2RA0; 2UWL; 2UWO; 2UWP; 2VH0; 2VH6; 2VVC; 2VVU; 2VVV; 2VWL; 2VWM; 2VWN; 2VWO; 2W26; 2W3I; 2W3K; 2WYG; 2WYJ; 2XBV; 2XBW; 2XBX; 2XBY; 2XC0; 2XC4; 2XC5; 2Y5F; 2Y5G; 2Y5H; 2Y7X; 2Y7Z; 2Y80; 2Y81; 2Y82; 3CEN; 3CS7; 3ENS; 3FFG; 3HPT; 3IIT; 3K9X; 3KL6; 3KQB; 3KQC; 3KQD; 3KQE; 3LIW; 3M36; 3M37; 3Q3K; 3SW2; 3TK5; 3TK6; 4A7I; 4BTI; 4BTT; 4BTU
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Apixaban | Drug Info | Approved | Thrombosis | [532210], [541527] |
BETRIXABAN | Drug Info | Approved | Venous thromboembolism | [889446] | |
Certoparin sodium | Drug Info | Approved | Deep vein thrombosis | [551871] | |
Coagulation Factor IX | Drug Info | Approved | Haemophilia B; Christmas disease | [533123], [550670] | |
Dalteparin Sodium | Drug Info | Approved | Hematology | [551871] | |
Danaparoid | Drug Info | Approved | Deep venous clots | [535201], [541886] | |
DU-176b | Drug Info | Approved | Atrial fibrillation | [524299], [542568] | |
Fondaparinux sodium | Drug Info | Approved | Venous thrombosis | [536361] | |
Lmw heparin | Drug Info | Approved | Coagulation | [551871] | |
Nadroparin calcium | Drug Info | Approved | Coagulation | [551871] | |
Rivaroxaban | Drug Info | Approved | Prophylaxis of deep vein thrombosis | [531783], [541524] | |
Human coagulation factor X | Drug Info | BLA submitted | Renal cancer | [550389] | |
BETRIXABAN | Drug Info | Phase 3 | Cerebrovascular ischaemia | [523883] | |
MELAGATRAN | Drug Info | Phase 3 | Discovery agent | [521709], [541520] | |
PRT4445 | Drug Info | Phase 3 | Bleeding | [549059] | |
Semuloparin | Drug Info | Phase 3 | Venous thromboembolism | [531405], [531982] | |
SSR-126517E | Drug Info | Phase 3 | Thrombosis | [521848] | |
SR-123781A | Drug Info | Phase 2/3 | Venous thrombosis | [521845] | |
Antistasin | Drug Info | Phase 2 | Attention deficit hyperactivity disorder | [531305] | |
EP-217609 | Drug Info | Phase 2 | Thrombosis | [549210] | |
GW-813893 | Drug Info | Phase 2 | Thromboembolism | [522136] | |
LY-517717 | Drug Info | Phase 2 | Thrombosis | [521582] | |
BI-11634 | Drug Info | Phase 1 | Thrombosis | [549573] | |
BIBT986 | Drug Info | Phase 1 | Thrombosis | [548355] | |
EP-42675 | Drug Info | Phase 1 | Thrombosis | [548235] | |
GCC-4401 | Drug Info | Phase 1 | Thrombosis | [524453] | |
R-1663 | Drug Info | Phase 1 | Blood coagulation disorders | [548346] | |
SSR-128428 | Drug Info | Phase 1 | Thromboembolism | [547951] | |
CS-3030 | Drug Info | Preclinical | Thrombosis | [548159] | |
Darexaban maleate | Drug Info | Discontinued in Phase 3 | Acute coronary syndrome | [547958] | |
Idraparinux | Drug Info | Discontinued in Phase 3 | Thrombosis | [546816] | |
Otamixaban | Drug Info | Discontinued in Phase 3 | Angina pectoris | [547363] | |
Octopamine | Drug Info | Discontinued in Phase 2a | Thromboembolic disorders | [525357], [539364] | |
DX-9065 | Drug Info | Discontinued in Phase 2 | Blood coagulation disorders | [526864], [545649] | |
DX-9065a | Drug Info | Discontinued in Phase 2 | Angina pectoris | [545649] | |
PD-348292 | Drug Info | Discontinued in Phase 2 | Thrombosis | [548310] | |
TAK-442 | Drug Info | Discontinued in Phase 2 | Thrombosis | [548667] | |
AVE-3247 | Drug Info | Discontinued in Phase 1 | Thrombosis | [547052] | |
DPC 423 | Drug Info | Discontinued in Phase 1 | Thrombosis | [547044] | |
EMD-503982 | Drug Info | Discontinued in Phase 1 | Thrombosis | [548116] | |
JTV-803 | Drug Info | Discontinued in Phase 1 | Thrombosis | [547277] | |
YM-75466 | Drug Info | Discontinued in Phase 1 | Thrombosis | [546826] | |
ZD-4927 | Drug Info | Discontinued in Phase 1 | Thrombosis | [546656] | |
Draculin | Drug Info | Terminated | Thrombosis | [545778] | |
Hirufaxin | Drug Info | Terminated | Thrombosis | [547022] | |
Nematode anticoagulant proteins | Drug Info | Terminated | Angina pectoris | [546177] | |
YM60828 | Drug Info | Terminated | Discovery agent | [546601] | |
Inhibitor | 1,2,3,4,6-penta-O-galloyl-beta-D-glucose | Drug Info | [534762] | ||
3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate | Drug Info | [527883] | |||
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine | Drug Info | [527397] | |||
5-desgalloylstachyurin | Drug Info | [534762] | |||
Antistasin | Drug Info | [535352] | |||
Apixaban | Drug Info | [549835], [549974] | |||
AVE-3247 | Drug Info | [531405], [531982] | |||
Azaphenylalanine derivative | Drug Info | [526986] | |||
Beta-Hydroxy Aspartic Acid | Drug Info | [551374] | |||
BI-11634 | Drug Info | [531405], [531982] | |||
BIBT986 | Drug Info | [528309] | |||
BMS-269223 | Drug Info | [530503] | |||
BMS-344577 | Drug Info | [530503] | |||
BMS-740808 | Drug Info | [529078] | |||
CASUARIIN | Drug Info | [534762] | |||
Chloroaniline 1 | Drug Info | [535710] | |||
CS-3030 | Drug Info | [531405], [531982] | |||
D-Pro-Phe-Arg chloromethyl ketone | Drug Info | [529454] | |||
Danaparoid | Drug Info | [535592] | |||
Darexaban maleate | Drug Info | [531926] | |||
DPC 423 | Drug Info | [535405] | |||
DX-9065 | Drug Info | [531405], [531982] | |||
DX-9065a | Drug Info | [535685] | |||
EMD-503982 | Drug Info | [531405], [531982] | |||
Fondaparinux sodium | Drug Info | [535484], [535819] | |||
Gamma-Carboxy-Glutamic Acid | Drug Info | [551393] | |||
GC-2107 | Drug Info | [531405], [531982] | |||
GCC-4401 | Drug Info | [531405], [531982] | |||
GW-813893 | Drug Info | [531405], [531982] | |||
Hirufaxin | Drug Info | [531405], [531982] | |||
Idraparinux | Drug Info | [549823] | |||
JTV-803 | Drug Info | [531405], [531982] | |||
Lefaxin | Drug Info | [535352] | |||
LY-517717 | Drug Info | [531405], [531982] | |||
M55113 | Drug Info | [535279] | |||
M55551 | Drug Info | [535566] | |||
MELAGATRAN | Drug Info | [528066] | |||
Molecule 11 | Drug Info | [535485] | |||
Octopamine | Drug Info | [537045], [537289] | |||
Otamixaban | Drug Info | [549823] | |||
PD-348292 | Drug Info | [549974], [551665] | |||
PEDUNCULAGIN | Drug Info | [534762] | |||
PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole) | Drug Info | [529193] | |||
PRT-064445 | Drug Info | [531405], [531982] | |||
R-1663 | Drug Info | [531405], [531982] | |||
RAZAXABAN | Drug Info | [529078] | |||
SC-83157 | Drug Info | [535728] | |||
Semuloparin | Drug Info | [531405], [531982] | |||
SF303 | Drug Info | [535405] | |||
SK509 | Drug Info | [535405] | |||
SK549 | Drug Info | [534887] | |||
SK554 | Drug Info | [535352] | |||
SN429 | Drug Info | [535728] | |||
SSR-126517E | Drug Info | [531405], [531982] | |||
T01312 | Drug Info | [535782] | |||
TAK-442 | Drug Info | [551717] | |||
Tellimagrandin II | Drug Info | [534762] | |||
Tick anticoagulant peptide | Drug Info | [535302], [535352] | |||
Tick anticoagulant peptide (TAP) | Drug Info | [535352] | |||
YM-75466 | Drug Info | [531405], [531982] | |||
YM-96765 | Drug Info | [535942] | |||
YM60828 | Drug Info | [535352] | |||
ZD-4927 | Drug Info | [531405], [531982] | |||
ZK-810388 | Drug Info | [528872] | |||
ZK-814048 | Drug Info | [528872] | |||
Modulator | BETRIXABAN | Drug Info | |||
Certoparin sodium | Drug Info | [525658], [534676], [536361] | |||
CI-1031 | Drug Info | ||||
Dalteparin Sodium | Drug Info | [556264] | |||
Draculin | Drug Info | [534730] | |||
DU-176b | Drug Info | [543603] | |||
EP-217609 | Drug Info | ||||
EP-42675 | Drug Info | [532552] | |||
Human coagulation factor X | Drug Info | [531405], [531982] | |||
Lmw heparin | Drug Info | [536361] | |||
Nadroparin calcium | Drug Info | [526062], [536361] | |||
Nematode anticoagulant proteins | Drug Info | ||||
PRT4445 | Drug Info | [531405], [531982] | |||
Recombinant coagulation factors | Drug Info | [531405], [531982] | |||
Recombinant Factor X | Drug Info | [531405], [531982] | |||
Rivaroxaban | Drug Info | [551871] | |||
SR-123781A | Drug Info | [535183] | |||
SSR-128428 | Drug Info | ||||
ZK-813039 | Drug Info | [528872] | |||
Activator | Coagulation Factor IX | Drug Info | [536124] | ||
Antagonist | DT-831j | Drug Info | [531405], [531982] | ||
EP-37 | Drug Info | [531405], [531982] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Complement and coagulation cascades | ||||
PANTHER Pathway | Blood coagulation | ||||
Pathway Interaction Database | Beta2 integrin cell surface interactions | ||||
PathWhiz Pathway | Coagulation | ||||
Reactome | Extrinsic Pathway of Fibrin Clot Formation | ||||
Intrinsic Pathway of Fibrin Clot Formation | |||||
Common Pathway of Fibrin Clot Formation | |||||
Gamma-carboxylation of protein precursors | |||||
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
WikiPathways | Complement and Coagulation Cascades | ||||
Human Complement System | |||||
gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
Blood Clotting Cascade | |||||
Formation of Fibrin Clot (Clotting Cascade) | |||||
References | |||||
Ref 521582 | ClinicalTrials.gov (NCT00074828) New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery. U.S. National Institutes of Health. | ||||
Ref 521709 | ClinicalTrials.gov (NCT00206089) Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events. U.S. National Institutes of Health. | ||||
Ref 521845 | ClinicalTrials.gov (NCT00338897) Dose Ranging Study in Elective Total Hip Replacement Surgery. U.S. National Institutes of Health. | ||||
Ref 521848 | ClinicalTrials.gov (NCT00345618) Clinical Study Assessing SSR126517E Injections Once-weekly in Pulmonary Embolism Therapeutic Approach. U.S. National Institutes of Health. | ||||
Ref 522136 | ClinicalTrials.gov (NCT00541320) Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR). U.S. National Institutes of Health. | ||||
Ref 523883 | ClinicalTrials.gov (NCT01583218) Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study). U.S. National Institutes of Health. | ||||
Ref 524299 | ClinicalTrials.gov (NCT01857622) Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment. U.S. National Institutes of Health. | ||||
Ref 524453 | ClinicalTrials.gov (NCT01954238) A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers. U.S. National Institutesof Health. | ||||
Ref 525357 | Juvenile hormone and octopamine in the regulation of division of labor in honey bee colonies. Horm Behav. 2002 Sep;42(2):222-31. | ||||
Ref 531305 | The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75. | ||||
Ref 531405 | Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011 Apr 1;117(7):1334-49. | ||||
Ref 531982 | Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. | ||||
Ref 535201 | A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001 Jun;85(6):950-7. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 539364 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2149). | ||||
Ref 541520 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6382). | ||||
Ref 541524 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6388). | ||||
Ref 541527 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6390). | ||||
Ref 541886 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6804). | ||||
Ref 542568 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7575). | ||||
Ref 545649 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004028) | ||||
Ref 545778 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004668) | ||||
Ref 546177 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006763) | ||||
Ref 546601 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009133) | ||||
Ref 546656 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009534) | ||||
Ref 546816 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010432) | ||||
Ref 546826 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010496) | ||||
Ref 547022 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012166) | ||||
Ref 547044 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012496) | ||||
Ref 547052 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012558) | ||||
Ref 547277 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014748) | ||||
Ref 547363 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015497) | ||||
Ref 547951 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020651) | ||||
Ref 547958 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020726) | ||||
Ref 548116 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022087) | ||||
Ref 548159 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022617) | ||||
Ref 548235 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023539) | ||||
Ref 548310 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024432) | ||||
Ref 548346 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024856) | ||||
Ref 548355 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024917) | ||||
Ref 548667 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027537) | ||||
Ref 549059 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031853) | ||||
Ref 549210 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033781) | ||||
Ref 549573 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041083) | ||||
Ref 550389 | FDA Accepts BPL's Amended BLA Submission for Coagadex (Coagulation Factor X, Human). BPL Bio Products Laboratory USA, Inc. | ||||
Ref 526062 | Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81. | ||||
Ref 526986 | Bioorg Med Chem Lett. 2004 Mar 22;14(6):1563-7.Thrombin inhibitors built on an azaphenylalanine scaffold. | ||||
Ref 527397 | Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. | ||||
Ref 527883 | J Med Chem. 2005 Dec 1;48(24):7592-603.3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. | ||||
Ref 528066 | Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. Epub 2006 Mar 6.Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. | ||||
Ref 528309 | Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9. | ||||
Ref 528872 | J Med Chem. 2007 Jun 28;50(13):2967-80. Epub 2007 May 31.Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. | ||||
Ref 529078 | J Med Chem. 2007 Nov 1;50(22):5339-56. Epub 2007 Oct 3.Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban,BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. | ||||
Ref 529193 | Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. Epub 2007 Nov 6.Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. | ||||
Ref 529454 | J Med Chem. 2008 Jun 12;51(11):3077-80. Epub 2008 May 7.Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. | ||||
Ref 530503 | Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. Epub 2009 Oct 23.Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. | ||||
Ref 531405 | Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011 Apr 1;117(7):1334-49. | ||||
Ref 531926 | The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol. 2013 Feb;75(2):440-9. | ||||
Ref 531982 | Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. | ||||
Ref 532552 | EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33. | ||||
Ref 534676 | Low molecular weight heparins for venous thromboembolism. Drug Ther Bull. 1998 Apr;36(4):25-9. | ||||
Ref 534730 | Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim Biophys Acta. 1998 Oct 23;1425(2):291-9. | ||||
Ref 534762 | J Nat Prod. 1998 Nov;61(11):1356-60.Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. | ||||
Ref 534887 | Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem. 1999 Jul 29;42(15):2760-73. | ||||
Ref 535279 | Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor. Chem Pharm Bull (Tokyo). 2001 Oct;49(10):1237-44. | ||||
Ref 535302 | Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol. 2001 Apr;1(2):169-75. | ||||
Ref 535352 | Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. | ||||
Ref 535405 | The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49. | ||||
Ref 535484 | Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev. 2002 Winter;20(1):37-52. | ||||
Ref 535485 | Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev. 2002 Winter;20(1):67-80. | ||||
Ref 535566 | Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1187-94. | ||||
Ref 535592 | Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6. Epub 2002 Oct 8. | ||||
Ref 535685 | DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost. 2003 Jan;89(1):112-21. | ||||
Ref 535710 | Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1023-8. | ||||
Ref 535728 | Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21. | ||||
Ref 535782 | Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search. J Mol Graph Model. 2003 Nov;22(2):105-14. | ||||
Ref 535819 | Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24. | ||||
Ref 535942 | Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem. 2004 May 1;12(9):2179-91. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 537045 | AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study. J Thromb Haemost. 2009 Apr;7(4):566-72. Epub 2009 Jan 24. | ||||
Ref 537289 | Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009 Jul;7(7):1143-51. Epub 2009 Apr 27. | ||||
Ref 543603 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359). | ||||
Ref 549835 | Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014 Sep;12(9):1545-53. | ||||
Ref 551665 | Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011 Apr;38 Suppl 1:S3-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.